夜夜撸撸 I 国产精品国产自产拍高清av I 香港三日本三级少妇66 I 这里只是精品 I 国产日比视频 I 高清国产天干天干天干不卡顿 I 三级免费黄色 I 国产免费久久精品 I 欧美熟妇喷潮xxxx I 国产成人自拍网站 I 在线视频97 I 久久精品99精品国产香蕉 I 国产精品18久久久久久不卡孕妇 I 伊人狠狠操 I 国产精品91一区二区 I 少妇高潮出水视频 I 精品视频在线看 I 这里只有精品2 I 亚洲欧美国产双大乳头 I 巨爆乳中文字幕爆乳区 I 国产偷国产偷高清精品 I 久草在线视频免赞 I 青青操超碰 I 99久久er热在这里只有精品15 I 亚洲日韩中文字幕 I 日本少妇被黑人猛cao I 国产亚洲色欲色一色www I 国产午夜无码片免费 I 亚洲精品国产乱码av在线观看 I 无码福利写真片视频在线播放 I 日本作爱视频 I 麻豆成全视频免费观看在线看 I 日本免费网站看大片视频 I 日韩成人午夜电影 I 女人被躁得好爽免费视频

網站首頁技術中心 > 寶藿苷I 分析標準品,HPLC≥98%
產品目錄
寶藿苷I 分析標準品,HPLC≥98%
更新時間:2025-12-22 點擊量:115

寶藿苷I

分析標準品,HPLC≥98%

Baohuoside I

CAS號:113558-15-9

分子式:C27H30O10

分子量:514.52

MDLMFCD15071140

別名:淫羊藿次苷II; 寶藿苷 I; 寶藿苷Ⅰ; 淫羊藿次苷II

貨號

規格/參數/品牌

價格

貨期

YJ-B20075-20mg

分析標準品,HPLC≥98%

500.00

現貨

YJ-B20075-200mg

分析標準品,HPLC≥98%

1700.00

現貨

A10019-20mg

分析標準品,含量96.0%,可溯源

1100.00

現貨

產品介紹

熔點:202-203℃

沸點:759.4℃ at 760mmHg

比旋光度:(c, 0.09 in MeOH)-121

外觀:黃色針狀結晶

溶解性:DMSO  :  ≥  32  mg/mL (62.19  mM)

儲存條件:2-8℃

注意:部分產品我司僅能提供部分信息,我司不保證所提供信息的權威性,僅供客戶參考交流研究之用。

參考文獻(42)

42. [IF=2.5] Zheng Junzuo et al."Pharmacokinetics of seven major components in Aβ1-42-treated rats after oral administration of an aqueous extract of Curculiginis Rhizoma and Epimedii Folium."Journal of Natural Medicines.2024 Nov;:1-16

41. [IF=3.8] Jialu Shen et al."Insights into inhibitory mechanisms: Unraveling the structure-activity relationship of dietary flavonoids on gut bacterial β-glucuronidase."Journal of Functional Foods.2024 Nov;122:106510

40. [IF=2.1] Jun-Tao Sun et al."Exploring the protective effect and mechanism of icariside II on the bladder in a rat model of radiation cystitis based on transcriptome sequencing."INTERNATIONAL JOURNAL OF RADIATION BIOLOGY.

39. [IF=4.4] Chen Yangfeng et al."In Vitro evaluation of the anti-pancreatic cancer activity of epimedium herb."Frontiers in Pharmacology.2024 Jul;15:

38. [IF=6.1] Xiuchun Li et al."Icariside II alleviates lipopolysaccharide-induced acute lung injury by inhibiting lung epithelial inflammatory and immune responses mediated by neutrophil extracellular traps."LIFE SCIENCES".2024 Jun;346:122648

37. [IF=6] Dong Xie et al."Pharmacodynamic material basis and mechanism of Tenghuang Jiangu Wan on osteoarthritis using UPLC-Q-TOF-MS integrated with target network pharmacology."Arabian Journal of Chemistry".2024 Apr;17:105711

36. [IF=1.6] Liu Huimin et al."Identification and Characterization of the Chemical Constituents of Qianlie Shule Capsules by UPLC-Q-Orbitrap-MS/MS."JOURNAL OF AOAC INTERNATIONAL".2024 Feb;:

35. [IF=8.4] Ting An et al."De novo biosynthesis of anticarcinogenic icariin in engineered yeast."METABOLIC ENGINEERING.2023 Nov;80:207

34. [IF=5.4] Yi-min Liu et al."Uncovering the key pharmacodynamic material basis and possible molecular mechanism of extract of Epimedium against liver cancer through a comprehensive investigation."JOURNAL OF ETHNOPHARMACOLOGY.2023 Dec;317:116765

33. [IF=5.572] Zhen Zhao et al."An integrated strategy combining network toxicology and feature-based molecular networking for exploring hepatotoxic constituents and mechanism of Epimedii Folium-induced hepatotoxicity in vitro."FOOD AND CHEMICAL TOXICOLOGY.2023 Jun;176:

32. [IF=6.208] Jiaqi Zhang et al."The Effect of Epimedium Isopentenyl Flavonoids on the Broiler Gut Health Using Microbiomic and Metabolomic Analyses."INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES.2023 Jan;24(8):7646

31. [IF=6.832] Li  Zhang et al."Erxian herbal pair enhances bone formation in infected bone nonunion models and attenuates lipopolysaccharide-induced osteoblastinhibition by regulating miRNA-34a-5p."Bioengineered.2022;13(6):14339-14356

30. [IF=6.208] Yu Yao et al."A Novel 3-O-rhamnoside: 2″-O-xylosyltransferase Responsible for Terminal Modification of Prenylflavonol Glycosides in Epimedium pubescens Maxim.."INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES.2022 Jan;23(24):16050

29. [IF=5.895] Fang Liu et al."Co-Immobilizing Two Glycosidases Based on Cross-Linked Enzyme Aggregates to Enhance Enzymatic Properties for Achieving High Titer Icaritin Biosynthesis."JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY.2022;XXXX(XXX):XXX-XXX

28. [IF=5.988] Li  Pin et al."Epimedium koreanum Nakai–Induced Liver Injury—A Mechanistic Study Using Untargeted Metabolomics."Frontiers in Pharmacology.2022 Jul;0:2288

27. [IF=1.902] Ting Zhang et al."The influence of essential oils from ZhaLi NuSi Prescription on the pharmacokinetics of its non-volatile components in normal rats."Biomedical Chromatography. 2021 Oct 21

26. [IF=2.886] Yangyang Guo et al."Baohuoside I via mTOR Apoptotic Signaling to Inhibit Glioma Cell Growth."Cancer Manag Res. 2020; 12: 11435–11444

25. [IF=2.886] Fubiao Ni et al."Baohuoside I Inhibits the Proliferation of Pancreatic Cancer Cells via mTOR/S6K1-Caspases/Bcl2/Bax Apoptotic Signaling."Cancer Manag Res. 2019; 11: 10609–10621

24. [IF=3.645] Hongmin Zhang et al."Simultaneous determination of five isoflavones in rat plasma by LC-MS/MS: Comparative pharmacokinetic characteristics of Puerariae lobatae radix in normal and type 2 diabetic rats."J Sep Sci. 2019 Aug;42(16):2592-2601

23. [IF=3.757] Congyan Liu et al."Enhanced hydrolysis and antitumor efficacy of Epimedium flavonoids mediated by immobilized snailase on silica."Process Biochem. 2019 Nov;86:80

22. [IF=4.36] Kun Shi et al."Epimedii Folium and Curculiginis Rhizoma ameliorate lipopolysaccharides-induced cognitive impairment by regulating the TREM2 signaling pathway."J Ethnopharmacol. 2022 Feb;284:114766

21. [IF=4.411] Zhenxian Qin et al."A Widely Metabolomic Analysis Revealed Metabolic Alterations of Epimedium Pubescens Leaves at Different Growth Stages."Molecules. 2020 Jan;25(1):137

20. [IF=3.263] Jing Yang et al."Icariside II induces cell cycle arrest and differentiation via TLR8/MyD88/p38 pathway in acute myeloid leukemia cells."Eur J Pharmacol. 2019 Mar;846:12

19. [IF=6.529] Congyan Liu et al."Icariin combined with snailase shows improved intestinal hydrolysis and absorption in osteoporosis rats."Biomed Pharmacother. 2017 Oct;94:1048

18.  Liu, Congyan, et al. "Icariin combined with snailase shows improved intestinal hydrolysis and absorption in osteoporosis rats." Biomedicine & Pharmacotherapy 94 (2017): 1048-1056.https:##doi.org/10.1016/j.biopha.2017.07.163

17.  Yang, Jing, et al. "Icariside II induces cell cycle arrest and differentiation via TLR8/MyD88/p38 pathway in acute myeloid leukemia cells." European journal of pharmacology 846 (2019): 12-22.https:##doi.org/10.1016/j.ejphar.2018.12.026

16.  許婷,黃萌萌,李瑞云,楊茹,劉麗芳,陳彥.多基原淫羊藿不同部位質量評價研究[J].中草藥,2020,51(01):190-196.

15.  劉聰燕,李瑞云,馬程遙,劉玉萍,瞿鼎,李曉琦,陳彥.殼聚糖交聯介孔二氧化硅固定化β-葡萄糖苷酶生物轉化淫羊藿苷研究[J].中草藥,2021,52(03):685-691.

14.  彭靜, 馬益華, 陳彥,. 固定化蝸牛酶同時生物轉化淫羊藿中4種黃酮苷[J]. 中成藥, 2016, 38(9):1984-1990.

13.  高霞, 陳彥, 王瑩,. 糊精濕法制粒對淫羊藿總黃酮酶解的影響[J]. 中成藥, 2014, 36(007):1392-1397.

12.  高霞, 劉璇, 陳彥,. 淫羊藿總黃酮的生物轉化過程分析[J]. 中國中藥雜志, 2013, 38(23):4079.

11.  劉聰燕, 高霞, 陳彥,. 淫羊藿總黃酮在骨質疏松大鼠體內的藥動學行為[J]. 中成藥, 2017, 39(008):1595-1600.

10.  劉聰燕, 高霞, 黃萌萌,. 淫羊藿總黃酮仿生酶解腸溶膠囊的制備及評價[J]. 中草藥, 2016(20).

9.  張燕. 大孔吸附樹脂分離純化淫羊藿EF5黃酮[J]. 北方藥學, 2015, 000(011):11-13.

8.  劉聰燕  高霞  陳彥 等. 仿生酶解腸溶膠囊提高淫羊藿總黃酮口服生物利用度的可行性研究[J]. 中國醫藥工業雜志  2016(9):1158-1164.

7.  王瑩  高霞  陳彥 等. 卡波姆對淫羊藿總黃酮酶解效果的影響[J]. 中國實驗方劑學雜志  2014  20(009):1-5.

6.  楊茹  劉聰燕  許婷 等. 5種大孔吸附樹脂對淫羊藿總黃酮的吸附特性考察[J]. 中國實驗方劑學雜志  2020  v.26(06):121-128.

5.  顧慧敏, 孫娥, 李杰,. 炮制輔料羊脂油對寶藿苷Ⅰ-膽酸鹽自組裝膠束形成與吸收的影響[J]. 中國中藥雜志, 2019, v.44(23):133-140.

4.  劉玉萍, 丁學芳, 黃萌萌,. 淫羊藿苷在不同骨質疏松大鼠模型中腸道吸收代謝研究[J]. 中國中藥雜志, 2016(13):2532-2537.

3.  高霞, 陳彥, 王瑩,. 淫羊藿苷仿生酶解過程的多因素考察[J]. 藥學學報, 2013(11):1716-1721.

2.  李瑞云  劉聰燕  許婷 等. 交聯納米SiO_2固定化蝸牛酶的制備表征及轉化淫羊藿苷研究[J]. 中草藥  2019  v.50;No.655(20):57-63.

1.  楊軼舜  張彤  丁越 等. 3種淫羊藿苷次生產物的制備及HPLC測定[J]. 中成藥  2020  042(003):779-782.

2011年開始我們致力于在生命科學領域生物醫學實驗技術及論文潤色服務,協助客戶各類實驗服務及論文潤色十余年,是您值得信賴的科研合作伙伴!

如果您受時間、試驗條件等限制而無法完成您的課題研究,歡迎您與我們聯系。

實驗技術服務:



滬公網安備 31011802001677號